Active substanceClobetasolClobetasol
Similar drugsTo uncover
  • Dermovate®
    cream externally 
  • Dermovate®
    ointment externally 
  • Cloveit®
    cream externally 
    VALEANT, LLC     Russia
  • Cloveit®
    ointment externally 
    VALEANT, LLC     Russia
  • Powourcourt
    cream externally 
  • Etreex
    shampoo externally 
    Galderma S.A.     Switzerland
  • Dosage form: & nbspcream for external use
    Composition:

    100 g of cream contain:

    active substance: clobetasol propionate 0.05 g;

    Excipients: paraffin (paraffin soft white), paraffin liquid, cetomacrogol, sodium phosphate monohydrate, sodium phosphate dihydrate, butylhydroxytoluene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, propylene glycol, purified water.

    Description:

    A homogeneous cream of white color.

    Pharmacotherapeutic group:glucocorticosteroid for topical application
    ATX: & nbsp

    D.07.A.D.01   Clobetasol

    Pharmacodynamics:

    Glucocorticosteroid for external use. It prevents the accumulation of neutrophils boundary, reduces the inflammatory exudation and production of lymphokines inhibits the migration of macrophages, reduces the intensity of infiltration and granulation processes, has a local anti-inflammatory, antipruritic, anti-allergic and anti-exudative effects.

    Pharmacokinetics:

    The average maximum concentration of clobetasol propionate is reached in the plasma 13 hours after the first application and 8 hours after repeated application to the healthy skin of 30 g clobetasol propionate in the form of 0.05% ointment and is 0.63 ng / ml. 10 hours after the application of the second dose (30 g) of clobetasol propionate in the form of a cream, its average maximum concentration in the plasma slightly exceeds that of the ointment. After 3 hours after a single application of 25 g of 0.05% clobetasol propionate ointment in patients with psoriasis and eczema, the average maximum plasma concentration in the plasma is 2.3 ng / ml and 4.6 ng / ml, respectively.

    The systemic metabolism of clobetasol propionate after percutaneous absorption has not been studied.

    Indications:
    - Psoriasis (excluding common plaque psoriasis);

    - Eczema (various forms);

    - Red flat lichen;

    - discoid lupus erythematosus;

    - зskin abolition, resistant to therapy with less active glucocorticosteroids for topical application.

    Contraindications:

    - Pink acne;

    - Acne vulgaris;

    - skin cancer;

    - nodular pruritus of Gaida;

    - perioral dermatitis;

    - perianal and genital itching;

    - bacterial, viral and fungal skin diseases (herpes simplex, chicken pox, skin tuberculosis, actinomycosis, etc.);

    - common plaque and pustular psoriasis;

    - hypersensitivity to the active and auxiliary substances of the drug;

    - age up to 1 year;

    - lactation period.

    Pregnancy and lactation:

    Glucocorticosteroids for topical application should not be used during pregnancy for a long time in large doses.

    The safety of the use of clobetasol propionate during lactation is not established.

    Dosing and Administration:

    The cream is applied a thin layer on the affected skin once or twice a day until the effect is obtained. Treatment can not be performed for more than 4 weeks without evaluating the need for continuation. To treat exacerbations of skin diseases, you can repeat short short courses by Powercourt. If more glucocorticosteroid therapy is needed, less active drugs should be used.

    In particularly resistant cases, especially in the presence of hyperkeratosis, the anti-inflammatory effect of Powucourt cream can be enhanced by applying a bandage of polyethylene film overnight to the area of ​​application of the drug, which is usually accompanied by a positive effect.In the future, the achieved effect can be maintained without the use of an occlusive dressing.

    Side effects:

    Long-term administration of glucocorticosteroids for topical application in large doses or applying them to large areas of the skin can be accompanied by systemic absorption with the subsequent development of symptoms of hypercorticoidism. The risk of developing this complication is increased in children, especially with the use of an occlusive dressing, while the diaper can serve as a bandage.

    Given the appointment Pow Powrothra to adult patients in a dosage of not more than 50 g per week, suppression of the pituitary and adrenal glands function is transient in nature with their rapid recovery immediately after the end of the course of treatment.

    Prolonged treatment with high-activity glucocorticosteroids for topical administration in large doses can cause atrophic changes in the skin, in particular, its thinning, the appearance of atrophic striae, dilatation of the superficial blood vessels, especially when applying occlusive dressings and when applying the drug to areas of the skin with folds. Skin pigmentation and hypertrichosis may develop.In rare cases, treatment of psoriasis with glucocorticosteroids for topical application (or their withdrawal) provokes the development of pustular psoriasis.

    Sometimes Powucourt can cause an exacerbation of the symptoms of the disease.
    Overdose:

    The development of acute overdose is unlikely. However, in case of chronic overdose or misuse, symptoms of hypercorticism may develop, which requires a gradual discontinuation of the drug under the supervision of a physician.

    Interaction:

    No data.

    Special instructions:

    Should be avoided glucocorticosteroids for topical administration for a long time, especially in the treatment of young children, as this can happen adrenal suppression. The use of Powourcott in children requires the supervision of a doctor at least once a week.

    On the face more often than in other areas of the body may appear atrophic skin changes as a result of prolonged use of local glucocorticosteroids.

    When applying the cream on the eyelids, care should be taken to ensure that the product does not get into the eyes, because this can cause glaucoma.

    Treatment of psoriasis topical corticosteroids may be accompanied by the development of recurrence of the disease, tolerance to the drug, generalized pustular forms of the disease, local or systemic toxic reactions due to violation of the skin barrier function, so it is particularly important close observation of the patient.

    When attaching a secondary infection, appropriate antibiotic therapy should be carried out. If any signs of generalized infection should stop the topical application of glucocorticosteroids and conduct appropriate treatment with antibacterial drugs.

    Warm moist conditions created with the application of an occlusive dressing, contribute to the emergence of a bacterial infection, so you should always clean the skin before applying a new bandage.

    The cream is not recommended to plant.

    Effect on the ability to drive transp. cf. and fur:

    It is unlikely that clobetasol propionate affects this ability.

    Form release / dosage:Cream for external use, 0.05%
    Packaging:

    For 15 grams in an aluminum tube having a nozzle with a closed end, with a lid having a piercing tip.

    Each tube together with the instruction for use is placed in a cardboard box.

    Storage conditions:

    Store in a dry, dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-007065/08
    Date of registration:04.09.2008
    The owner of the registration certificate:Glenmark Pharmaceuticals Co., Ltd.Glenmark Pharmaceuticals Co., Ltd. India
    Manufacturer: & nbsp
    Representation: & nbspGLENMARK PHARMACEUTICALS LTD. GLENMARK PHARMACEUTICALS LTD. India
    Information update date: & nbsp29.07.2015
    Illustrated instructions
      Instructions
      Up